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Abstract
Background: Whilst the imputed role of High Risk (HR) HPV infection in the development of cervical lesions and
cancer has been established, the high number of HPV genotypes that Female Sex workers (FSW) harbour warrants
that the synergistic effects of potential HR (pHR) and HR HPV genotypes be elucidated to assess the potential
impact of prophylactic vaccines. This population in Kenya also harbours a number of other vaginal infections and
STIs, including bacterial vaginosis (BV), trichomonas vaginalis (TV) and candida spp.
The aims of this cross-sectional analysis in Kenya are to explore the epidemiology of abnormal cytology and the
pairing of pHR/HPV genotypes in HIV-negative and HIV-infected FSW.
Methods: A cross-sectional study design of 616 FSW from Western Kenya aged between 18 and 61 years during
2009–2015 using a peer recruitment sampling strategy.
Results: Of the 599 FSW who underwent cytological examination, 87 had abnormal cytology (14.5%; 95% CI: 12.0–
17.6%). A combined prevalence of HPV16 and 18 (29.6%; 95% CI: 22.2–37.8%) was observed in abnormal cytology.
HPV 53 and 51 were the most observed pairing in FSW with abnormal cytology. Significant adjusted associations
were found between abnormal cytology and TV (aOR: 30; 95% CI: 14.1–62.9), multiple HR HPV (aOR: 3.7; 95% CI: 1.9–
7.3), HPV 51 (aOR 3.7; 95% CI 1.6–8.6) and HPV 52 (aOR 6.1; 95% CI: 2.8–13.3).
Conclusion: HPV 51 and 52 were independently associated with abnormal cervical cytology in both HIV negative/
positive FSW. The strong association between TV and cervical dysplasia and the high percentage of FSW
harbouring more than one STI underscore the need for enhanced STI management within the framework of
cervical cancer prevention.
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Background
Human Papilloma Viruses (HPV) are double-stranded
DNA viruses which are now deemed to be the chief etio-
logical agents in cervical intraepithelial neoplasias and can-
cers [1]. High risk (HR) genotypes, which are associated
with cervical cancer include HPV genotypes 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, 68 while HPV types 26,
53, 67, 70, 73 and 82 are now classified as possible carcino-
genic, and low risk (LR) HPV genotypes considered benign
include 6, 11, 42, 43, and 44 [2]. The 15 HR oncological
viral strains, which have been identified can be broken
down into different species: the HPV 16 group (alpha-9) of
the alpha-papillomavirus genus (HPV 31, HPV33, HPV 35,
HPV 52, and HPV 58) and the HPV 18 group (alpha-7)
(HPV39, HPV 45, HPV 59, and HPV 68).
Cervical intraepithelial neoplasia (CIN) can be histo-
logically graded into mild dysplasia (CIN 1), moderate
dysplasia (CIN 2), and severe dysplasia to carcinoma in
situ (CIN 3). Several studies have reported a robust
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association between HIV and HPV co-infection and
therefore the development of CIN and genital cancer, [3,
4] along with a persistence and recurrence of pre-
invasive cervical lesions, CIN 2 or CIN 3 [5].
It is well recognized that among the 14 HR HPV geno-
types, HPV 16 and 18 are associated with approximately
two thirds of all invasive cervical carcinomas [6]. After
HPV16/18, data confirm HPV31/33/35/45/52/58 as the
most frequently detected genotypes in Invasive Cervical
Cancer (ICC) worldwide [7, 8].
Prophylactic vaccines against HPV 16 and 18 are currently
being rolled out across the globe for the prevention of cervical
cancer, which is likely to yield a significant impact on the
future burden of cervical cancer, particularly in sub Saharan
Africa, where screening is scarce. Although the bivalent/
quadrivalent vaccines, including the LR HPV 6 and 11 consti-
tute a crucial milestone in cervical cancer prevention in HIV-
negative women, epidemiological data available suggest that in
HIV positive populations, HPV 16 has shown to be frequent,
but not as predominant as seen in most HIV negative popula-
tions [9, 10]. Moreover, HIV immunosuppression has been
linked to multiple HPV infection [11, 12]. Concomitant
infection with multiple HPV genotypes has been found to be
attributable to the inability to clear HPV infections as well as
to the reactivation of latent HPV infections; both occurring as
a consequence of immune suppression [13, 14].
Also, epidemiological knowledge of pHR HPV types is
highly limited, mainly because commercial molecular as-
says focus on HR HPV genotypes. There is a paucity of
data on these genotypes in HIV positive women with ab-
normal cytology, notwithstanding their potential enhanced
role in cervical dysplasia development in HIV positive
patients [15, 16].
In Kenya, the Ministry of Public Health and Sanitation
has developed a comprehensive cervical cancer preven-
tion strategy, entailing plans for administrating quadriva-
lent vaccine to preteen girls in the near future. Currently
they are running the pilot programme Kituwi in Eastern
Kenya and awaiting approval for nationwide rollout and
successful global funding [17]. The not yet commercialized
nonavalent vaccine in Kenya, containing additional HPV
types HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antigens may
have the ability to prevent 90% of ICC cases worldwide.
In Kenya, as in many parts of sub-Saharan Africa, where
the penal code specifically penalizes prostitution [18],
FSW bear the greatest burden of HIV and STI infections.
Concomitant STIs and vaginal infections may lead to pro-
longed HPV infection, which may in turn increase the risk
of CIN [19, 20]. Bacterial vaginosis (BV) and Trichomonas
vaginalis (TV), have been associated with an increased
risk of squamous intraepithelial lesions and/or CIN based
on biopsy results [21, 22].
As early as 1985, a study reported that HIV prevalence
was as high as 61% among a group of FSW in Nairobi
[23]. A recent study reported that in Kenya, 5% of the
urban female population of reproductive age could be
sex workers [24].
The objectives of this analysis were primarily to assess
genotype-specific distribution of pHR/HR HPVs in FSW
with abnormal cytology, as well as the pairing prevalence
of certain pHR/HR HPV genotypes found in HIV nega-
tive and HIV infected women with abnormal cytology;
secondly, to investigate which HPV genotypes and other
variables were associated with abnormal cytology.
Methods
Study design
A cross-sectional design was used to explore associa-
tions between abnormal cytology and pHR/HR HPV ge-
notypes. This cross-sectional study based on record
reviews adhered to the methodological guidelines rec-
ommended in the STROBE document on observational
studies [25].
Women were excluded if they were pregnant, <18 years
of age, had a history of cervical dysplasia or cancer, had
current abnormal bleeding or bloody discharge, and/or
had a hysterectomy. Snowball sampling was undertaken
instead of randomized sampling, which is an often used
strategy for locating difficult-to-reach and stigmatized
populations [26]. This involved a sample of women en-
gaged in sex work being recruited through informational
gatherings, snowball sampling and neighborhood out-
reach. Inclusion criteria for the study entailed being fe-
male, giving consent after being explained the objectives
of the study, and having engaged in sex in exchange for
money, goods, services, or drugs in the last three months.
In order to reduce friendship bias, a limit of referral of 10
FSW was established. This activity was undertaken by
means of an extensive community outreach program by
Gynocare Women and Fistula Hospital, two non-
governmental organizations specializing in reproductive
health, to identify women with obstetric fistula, STI
screening and cervical screening in Western Kenya. The
screening was supported by Gent University, Belgium.
Sample size
The sample size was calculated to allow for a prevalence
of at least 15% for abnormal cytology, [27] with a confi-
dence interval of 95% and a power of 80%.
Data collection
Structured questionnaire
A structured paper questionnaire was privately adminis-
tered by trained interviewers covering socio-demographic
characteristics, and sexual behavior. Participants were of-
fered testing for HIV and HPV. HIV results were disclosed
to participants and women infected with HIV received
counseling and treatment.
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Specimen collection and laboratory testing
A gynaecological examination was performed using a
swab. Candida colonization was diagnosed by Gram stain;
bacterial vaginosis was scored according to Nugent’s cri-
teria. Infection with Trichomonas vaginalis was diagnosed
by PCR, using a validated method which was part of the
HPV genotyping essay.
A HIV diagnosis was performed using rapid immunoas-
says: Uni-Gold™ Recombigen® HIV (Trinity Biotech plc,
Bray, Ireland) and Determine® HIV-1/2 (Abbott Japan co
Ltd, Minato-Ku, Tokyo, Japan). In the case of indetermin-
ate results, an enzyme-linked immunosorbent assay was
used to confirm HIV status.
Biologic specimens
Cervical samples were collected using a cervix brush
(Cervex-brush®, Rovers®, Oss, The Netherlands), and cer-
vical cytology was assessed with conventional Papanico-
laou (Pap) smears. Slides were read by a cytologist with
master level training, supervised by a pathologist. An
external cytopathologist provided quality control. The
Bethesda Reporting System was used for cytological
classification [28].
The cervix brush tips were preserved in a liquid-based
cytology collection medium (SurePath®, Tripath Imaging
Inc., Burlington, North Carolina, USA) and stored at 4 °C
until further processing.
Ethical approval
Ethical approval for the study was obtained from the
Institutional Research and Ethics Committee at the MOI
University in Kenya (No 000187) on August 11th, 2011.
Statistics and data analysis
Data analysis was done using STATA version 12 (Stata-
Corp LP, College Station, TX). Due to incomplete infor-
mation about the study samples, we checked whether the
missing data (10%) were randomly distributed by perform-
ing the Little’s MCAR test. Continuous variables were
then converted into categorical. Age was dichotomized
into ≥30 years and <30 years; this categorization was used
to reflect the WHO 2014 guideline concerning cervical
screening. The number of pHR/HR HPV co-infections
was also dichotomized as a categorical variable with 1 and
≥2 genotypes.
We first described the distribution of pHR/HR HPV
types observed among women with both normal cytology
and abnormal cytology, for which the overall prevalence
and 95% confidence intervals (95% CI) based upon normal
distributions were calculated.
To examine patterns of clustering of high-risk HPV
types, the prevalence of pHR/HR HPV genotypes in pres-
ence of another pHR/HR HPV genotypes by abnormal cy-
tology was calculated, which was defined as the proportion
of women with abnormal cytology who were positive for
the pHR/HR HPV genotypes. The prevalence of pairings
detected in women with HSIL was also calculated.
The variables were explored by means of tabulation and
cross-tabulation. The χ2 test was used to assess whether
there was an association between CIN 2+ and various risk
factors. In building the regression models, age, STIs and
multiple pHR/HR HPV genotypes tested were entered. A
multivariable logistic regression analysis was performed to
assess the association between pHR/HR HPV genotypes
and abnormal cytology, ASC-US or higher, the main out-
come of interest and to simultaneously control for potential
confounders. The Likelihood Ratio Test (LRT) was used to
measure the association of each variable with the outcome.
To assess for a possible interaction due to age, logistic
regression models were fitted with and without the
interaction term; significance for interaction was then
checked through visual inspection of the OR and LRT.
Statistical significance was considered at p ≤ 0.05.
Results
Out of the 616 participants, data from only 599 partici-
pants could be analysed because of the quality of the
specimen. Missing values were observed for BV (61), TV
(7) and candida spp (7). The Little’s MCAR test revealed
that the missing values were randomly distributed
among the participants (p = 0.4), therefore unlikely to
have introduced information bias.
The mean age of study participants was 28 years and me-
dian parity was 2 (range: 0–7 children). Regular condom
use, which was defined as always or almost always was
reported in 21.7% of 369 women. (95% CI = 17.6–26.2%).
The median number of partners in the past week was 4
(IQR: 2–7). Table 1 depicts the prevalence of categories for
age and sexual behavior.
Of the 616 FSW who underwent cytological examination,
512 (85.5%: 95% CI: 82.4–88.2) had normal cytology, 87
had abnormal cytology (14.5%; 95% CI: 12.0–17.6%) and 17
were excluded due to poor quality of the sample, leaving
599 participants on whom we could perform the analysis.
Of the FSW population, 192 FSW were HIV positive, of
Table 1 Reports the prevalence of categories for age and
sexual behaviour
Socio demographic variables Percentage (95% CI)
>30 years 40.1% (95% CI: 36.2–44.1)
≤30 years 59.9% (95% CI: 55.9–63.8)
Sexual behavior:
> 4 sexual partners the past week 1.9% (95% CI:1.0–3.3)
≤ 4sexual partners 98.1% (95% CI: 96.7–99.0)
Regular use of condom 21.7% (95% CI 17.6–26.2)
No regular use of condom 78.3% (95% CI: 73.8–92.3)
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which 27.1% (95% CI: 20.9–34.0%) had abnormal cytology.
Table 2 in annex reports the prevalence of cervical abnor-
malities observed in the sample (N = 616).
The prevalence of pHR/HR HPV and multiple pHR/HR
co-infections in the 616 FSW was 57.7 and 32.8% res-
pectively. In HPV infected FSW, HIV-infected FSW
had a significantly higher number of co-infections (2.0)
than HIV negative FSW (0.9), p < 0.001.
The prevalence of BV in this population was 48.3%,
followed by TV 31.4%, and candida spp 19.9%. FSW with
BV had the highest prevalence of multiple pHR/HR co-
infections with 53.4%, followed by TV, and candida spp,
38.8and 23.9% respectively. Table 3 reports the prevalence
of each HPV genotypes and vaginal infections/TV.
Normal and abnormal cytology and each HPV genotypes
The combined prevalence of HPV 16 and HPV 18 was
27.1%, and of the two pHR HPV genotypes tested, HPV
53 and 66, 20.8% (95% CI: 17.6–24.2%). In women with
abnormal cytology, we observed a multiple pHR/HR HPV
genotype prevalence of 65.5%. See Table 4 in annex, which
reports the prevalence of each HPV genotypes.
Potential HR HPV in abnormal cytology
HPV 53 and HPV 66 were found as a stand-alone pHR
HPV genotype in two LSIL cases.
Pairings of pHR/HR HPV genotypes in abnormal cytology
A higher prevalence of pairings in abnormal cytology were
observed in HIV infected FSW than HIV negative FSW.
The most frequently observed pairings in HIV- negative
FSW were HPV 18 and 31 (n = 3) occurrences, and HPV
31 and 52 (n = 2), involving genotypes phylogenetically
related to the HPV 16.
In HIV-infected women, HPV 53 and HPV 51 are
observed in 5 of the most prevalent pairings, followed by
HPV 16, observed in 4 of the most prevalent pairings.
Whilst in HIV negative FSW, the most prevalent co-
infection pairings exhibited a mixed alpha 9-alpha 7 com-
bination or a homogenous alpha 9 pattern, in HIV infected
women, the non-alpha 9/7 pHR HPV genotypes, HPV 53
(alpha 6) and HPV 51 (alpha 5) figure prominently. See
Table 5 in annex which depicts the most prevalent pairing
occurrences in women with abnormal cytology and HSIL.
Risk factors for abnormal cytology
In the univariate analysis, age did not appear to be asso-
ciated with abnormal cytology: women under 30 years of
age have a crude OR 1.1 (95% CI: 0.7–1.8 p = 0.6) of
having abnormal cytology compared to older women.
Table 2 Reports the prevalence of cervical abnormalities
observed in the sample (N = 616)
Cytological status n % of FSW (95% CI)
Normal cytology 512 85.5% (82.4–88.2)
ASC-US 10 1.7% (0.8–3.04)
LSIL 63 10.5% (8.2–13.3)
HSIL 14 2.3% (12.8–3.9)
Excluded samples due to poor quality 17 2.8%
Table 3 Reports the prevalence of each HPV genotypes and
vaginal infections/TV
pHR/HR HPV Genotype Frequency (n) Percentage
(N = 616)
95% CI
HPV 16 (N = 616) 99 16.10% 13.3%–19.2%
HPV 18 (N = 616) 68 11.04% 08.7%–13.8%
HPV 31 (N = 616) 49 8.00% 5.9%–10.4%
HPV 33 (N = 616) 2 0.30% 0.04%–1.2%
HPV 35 (N = 616) 70 11.40% 9.0%–14.1%
HPV 39 (N = 616) 48 7.80% 5.8%–10.2%
HPV 51 (N = 615) 52 8.50% 3.7%–7.4%
HPV 53 (N = 616) 68 11.04% 8.7%–13.8%
HPV 56 (N = 616) 45 7.30% 5.4%–9.7%
HPV 58 (N = 616) 30 4.90% 3.3%–6.9%
HPV 59 (N = 616) 75 12.20% 9.7%–15.02%
HPV 66 (N = 616) 60 9.70% 7.5%–12.4%
HPV 68 (N = 616) 9 4.90% 3.3%–6.9%
Vaginal infections and TV
BV (N = 555) 268 48.30% 44.06%–52.5%
TV (N = 609) 191 31.4% 27.6%–35.2%
Candida (N = 609) 121 19.90% 16.8%–23.3%
Table 4 Reports the prevalence of each HPV genotype in
women with abnormal cytology
HPV genotype Abnormal cytology % (N = 87) 95% CI
HPV 16 24 28.6% 19.2–39.5
HPV 18 15 17.9% 10.0–27.0
HPV 31 13 15.5% 8.5–25.0
HPV 33 1 1.2% 0.03–6.5
HPV 35 18 21.4% 13.2–31.7
HPV 39 13 15.5% 8.5–25.0
HPV 45 9 10.7% 5.0–19.4
HPV 51 18 21.4% 13.2–31.7
HPV 52 26 31.0% 21.3–42.0
HPV 53 21 25.0% 16.2–35.6
HPV 56 13 15.5% 8.5–25.0
HPV 58 4 13.3% 3.8–30.7
HPV 59 17 23.6% 14.4–35.1
HPV 66 9 10.7% 5.0–19.4
HPV 67
HPV 68 4 4.8% 1.3–11.7
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A very strong significant association was found between
TV and abnormal cytology OR: 30.0 (95% CI: 14.1–62.9)
adjusting for age and pHR/HR HPV genotypes, BV and
candida spp and HIV.
A statistically significant OR, adjusted for age was
found for multiple HPV and abnormal cytology com-
pared to single HPV genotype infection. This association
decreased but remained significant (OR; 3.9; p < 0.001;
95%CI: 1.9–7.8) when adjusted for HIV.
Whilst all pHR/HR HPV genotypes were significant pre-
dictors of abnormal cytology, when adjusted for age pHR/
HR HPV genotypes co-infections, HIV, BV, TV, and
candida spp these associations became statistically insig-
nificant, except for HPV 51 and 52. Table 6 in annex
depicts the age, BV, TV and candida spp adjusted associ-
ation between specific pHR/HR HPV genotypes and
abnormal cytology.
As no interaction terms were significant, no result
reflecting the differential impact for that particular out-
come was presented.
Discussion
Summary of results
In the present study, we observed a high prevalence of
women harbouring more than two pHR/HR HPV geno-
types, which was significantly higher in HIV-1–infected
women, consistent with results of several studies illus-
trating that HIV-1–infected women not only have a
greater prevalence of HR-HPV infection but multiple
coinfections [29, 30].
Our observations are in agreement with those of a
large study on multiple HPV infections in Costa Rica in
which young healthy women with multiple infections
were at significantly increased risk of CIN 2+, Although
our findings of an association between TV and abnormal
cytology are congruent with other observations [31]
demonstrating an association between TV and abnormal
cytology, [32, 33] our study suggest an unprecedented
strong association.
After adjusting for age and multiple pHR/HR HPV co-
infections, BV, TV and candida spp, no significant associ-
ation was observed between any single pHR/HR HPV and
abnormal cytology, except for HPV 51 and 52 in both
HIV negative and positive women. This is incongruent
with our previous findings in an exclusively HIV-infected
study population in Belgium, [34] in which only the asso-
ciation between HPV 39 and abnormal cytology became
statistically significant.
In contrast to HPV 31 and 58 being the most observed
frequent pairing in Brazil in HIV infected women, and
HPV 31 and 66 and HPV 39 and 52 in our Belgian study
population, in this FSW study population, HPV 31, 52 and
66 do not figure prominently within pairings observed in
HIV-infected women despite a higher prevalence of HPV
52 than HPV 53.
Also, our high prevalence of women with abnormal cy-
tology without any detected HPV genotypes can be attrib-
uted to our testing of only 18 genotypes out of the over 200
HPV types described. Whilst some types may be inducing
low grade lesions, they may also lack a cancer-initiating
capacity.
Strengths and limitations
Our major strength was that all cervical smears were his-
tologically confirmed and the high sensitivity of the HPV
DNA diagnostics employed. However, whilst our sample
was large, the number of FSW with abnormal cytology
was small, which precluded us from exploring particular
co-infection patterns as a risk factor. Moreover, due to our
lack of behavioral and clinico-epidemiological data, in-
cluding smoking, CD4 count, HAART use or the presence
of other co-infections, we have not been able to adjust for
these potential confounders, nor assess whether these fac-
tors were associated with cervical abnormalities. Also,
there may be potential for selection bias as FSW with
similar characteristics may have been sampled, as a result
of the convenience sampling method used. However, a
convenience sampling strategy may have inadvertently ex-
cluded those FSW operating in a more clandestine fashion
and thereby not benefitting from a social network.
A limitation related to a cross sectional study design
may be the lack of data concerning age of acquisition of
Table 5 Most prevalent pairing occurrences in women with
abnormal cytology and HSIL
Prevalent pairings in abnormal cytology
in HIV-negative women
Occurrences
(n)
% in abnormal
cytology
HPV 18 and 31 2 3
HPV 31 and 52 7 2
Prevalent pairings in HIV infected women with abnormal cytology
HPV 16 and 39 2 6
HPV 16 and 52 9 7
HPV 16 and 51 4 5
HPV 16 and 53 10 7
HPV 18 and 52 12 5
HPV 18 and 53 8 5
HPV 31 and 51 2 5
HPV 35 and 51 2 5
HPV 35 and 53 4 7
HPV 45 and 53 0 6
HPV 45 and 59 2 5
HPV 51 and 53 2 7
HPV 51 and 56 1 6
HPV 52 and 56 3 6
HPV 53 and 56 1 5
Menon et al. Infectious Agents and Cancer  (2017) 12:2 Page 5 of 8
HIV infection since it is possible this may have occurred
too late in life for some of the women in our study to in-
fluence abnormal cytology. Similarly, an analysis of a cross
sectional study for exploring associations between mul-
tiple HPV genotypes and abnormal cytology may have
inherent limitations as infections may have been acquired
concurrently or sequentially, therefore, resulting in the
criterion of temporality for causation not being met. This
may have an impact as immunologic responses may differ
following concurrent acquisition of multiple HPV geno-
types from infections that are acquired sequentially.
Implications for vaccination programs
The only significant association observed between ab-
normal cytology and HPV 51 and HPV 52 underscore
the need for post quadrivalent and nonavalent vac-
cine surveillance in both HIV negative and HIV
infected FSW.
In light of a high prevalence of multiple HR HPV in-
fections in this FSW HIV-negative and infected popula-
tion, it will need to be elucidated whether cross
protection may be hampered by the additional burden
due to other synergistic relationships among HR HPV
genotypes present. A recent systematic review and meta-
analysis [35] found that bivalent Cervarix© vaccine from
GlaxoSmithKline had better cross protection against
HPV 31 in persistent infection, but that efficacy against
persistent infections with types 31 appeared to decrease
with longer follow-up, suggesting a waning of cross-
protection. It still remains to be determined whether a
cross protection can be extrapolated to HIV-infected
women and in presence of multiple HR HPV genotypes.
Moreover, with a high prevalence of the pHR HPV 53
in pairings with the vaccine preventable HPV 16 and
HPV 18 in HIV infected women, it will need to be deter-
mined how HPV 53 will fare within the vacuum that en-
sues the quadrivalent vaccine [36]. In addition, given the
high median number of pHR/HR HPV genotypes har-
boured by this population, the synergies between not
only two pHR/HR HPV genotypes need to be deter-
mined but within a context of other prevalent genotypes,
capable of inducing cervical cancer genesis. Whether
Gardasil and Cervarix can attain a 70% reduction of cer-
vical cancer may be contingent upon the natural history
of the imputed pHR/HR HPV genotypes in cancer gen-
esis along with their synergistic effects.
Our very high association between TV and cervical
dysplasia underscores the need for STI management to
be integrated within cervical cancer prevention program.
Furthermore, the biological interaction between TV and
HPV and its subsequent capacity to induce progression
of cervical dysplasia should be further explored. More-
over, the impact of immune modulating infections, such
as tuberculosis, malaria and helminthic infections on
cervical disease progression should be elucidated in HIV
triple co-infected women with HPV and TV.
Table 6 Association between vaginal infections, TV, specific pHR/HR HPV genotypes and abnormal cytology; OR from Logistic
regression; p-value from LRT
Vaginal infections and STIs OR Model 1 (95% CI) p-value OR Model 2 (95% CI) p-value
BV 0.9 (0.6–1.5) 0.8 0.8 (0.5–1.4) 0.5
TV 24.8 (12.7–48.3) <0.001 30.0 (14.1–62.9) <0.001
Candida spp 1.0 (0.5–1.7) 1.0 0.9 (0.5–1.7) 0.7
Multiple HPV infection 5.3 (2.9–9.7) <0.001 3.7 (1.9–7.3) <0.001
HPV 16 1.9 (0.8–4.5) 0.1 1.2 (0.5–3.2) 0.5
HPV 18 0.8 (0.3–2.1) 0.7 1.04 (0.4–2.8) 0.9
HPV 31 0.5 (0.2–1.5) 0.2 0.6 (0.2–1.7) 0.3
HPV 33 3.9 (0.05–293.9) 0.5 2.8 (0.03–254.6) 0.6
HPV 35 1.3 (0.6–3.0) 0.5 1.1 (0.5–2.7) 0.9
HPV 39 3.3 (1.3–8.7) 0.03 2.5 (0.9–7.1) 0.09
HPV 51 3.7 (1.6–8.6) 0.002 3.7 (1.5–9.0) 0.004
HPV 52 6.1 (2.8–13.3) <0.001 4.0 (1.6–8.2) 0.002
HPV 53 2.0 (0.8–4.9) 0.1 1.4; (0.5–3.8) 0.5
HPV 56 2.5 (1.0–6.6) 0.06 2.0 (0.7–5.7) 0.2
HPV 58 0.9 (0.2–3.6) 0.9 1.1 (0.3–5.2) 0.9
HPV 66 1.2 (0.5–3.0) 0.7 1.0 (0.4–3.0) 0.9
HPV 68 1.7 (0.2–17.0) 0.7 0.8 (0.1–7.4) 0.8
Model 1: OR adjusting for age, pHR/HR HPV genotypes, vaginal infections/TV
Model 2: OR adjusting for age and pHR/HR genotypes, vaginal infections/TV and HIV
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Conclusion
Co-infection with pHR/HR HPV genotypes was more
strongly associated with abnormal cytology than any
single high-risk HPV. In light of the high prevalence of
multiple pHR/HR HPV genotypes harboured by FSW and
especially HIV infected women, its micro epidemiology in
cervical carcinoma in HIV positive women needs to be
explored in order for the vaccine efficacy to be assessed.
Whilst the quadrivalent vaccine may be effective in re-
ducing the prevalence of abnormal cytology in HIV
negative and HIV infected FSW, the high presence of
multiple infections with HPV 16 requires that the micro
epidemiology of concurrent be elucidated. In particular,
the high prevalence of the non alpha 9 and 7 genotypes,
HPV 51 and HPV 53 observed in pairings with HPV 16
and HPV 18 in HIV infected FSW requires further
characterization.
These current gaps in epidemiology underscore the
need for FSW, HIV negative or positive to be regu-
larly monitored in the post quadrivalent/nonavalent
vaccine era.
The strong association observed between TV and
cervical dysplasia as well as the high percentage of FSW
harbouring more than one vaginal infection/STI begs for
the elucidation of synergistic interactions between mul-
tiple STIs to be better assessed as factor(s) for cervical
dysplasia and for a wider encompassing cervical cancer
prevention framework.
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